Breast Cancer, Fabi (Aiom): "13 Thousand Patients per Year Candidate for Genomic Testing"
12 Articles
12 Articles
In women at an early stage, they reduce the use of chemotherapy by 48% but we are still far from the minimum target of 13 thousand per year.
Il Tempo
Rome, 9 Sep. (Adnkronos Salute) - "From 2020 to today in Italy more than 30 thousand genomic tests have been prescribed for the treatment of breast cancer at an early stage. They are now fundamental tests in everyday clinical practice and may indicate the risk of neoplasm reappearing. At the same time they have a predictive role in identifying which patients benefit from chemotherapy, after surgery. Each year should be prescribed to at least 13 …
From 2020 to today in Italy more than 30 thousand genomic tests have been prescribed for the treatment of breast cancer at an early stage. (ANSA)
(Adnkronos) "After about 13 thousand patients potentially candidates each year, the average of the tests carried out between 2024 and 2025 exceeded 2,500. It should be considered that the National Fund dedicated to genomic tests is no longer sufficient. Diagnosis increases, the number of suitable patients increases and we have learned [...]
canaledieci.it
Giornale Radio(Adnkronos) ==After about 13,000 patients who are potentially candidates each year, the average number of tests carried out between 2024 and 2025 exceeded 2,500. It should be considered that the National Fund dedicated to genomic tests is no longer sufficient. Diagnosis increases, the number of suitable patients grows and we have learned [...]
(Adnkronos) - "After about 13,000 potentially candidate patients each year, the average of the tests carried out between 2024 and 2025 exceeded the quota
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
